Tissue slide-based microRNA characterization of tumors: How detailed could diagnosis become for cancer medicine?

Expert Review of Molecular Diagnostics

Volumn 14, Issue 7, 2014, Pages 853-869

  Sempere, Lorenzo F ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

biomarker; contextual information; diagnostics; formalin fixed paraffin embedded tissues; in situ hybridization; locked nucleic acid; miR; miRNA; multiplex assay

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; TUMOR MARKER; PARAFFIN;

ANALYTIC METHOD; CANCER CELL; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER TISSUE; DEVICE APPROVAL; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SEQUENCING; HUMAN; IMAGE ANALYSIS; IN SITU HYBRIDIZATION; LABORATORY AUTOMATION; MOLECULAR PROBE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); REPRODUCIBILITY; REVIEW; RNA ANALYSIS; STROMA CELL; STUDY DESIGN; TISSUE FIXATION; TISSUE SECTION; VALIDITY; BIOSYNTHESIS; DNA MICROARRAY; GENETICS; HIGH THROUGHPUT SCREENING; MOLECULAR DIAGNOSIS; NEOPLASMS; PROCEDURES;

GENE EXPRESSION PROFILING; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAFFIN EMBEDDING; TUMOR MARKERS, BIOLOGICAL;

EID: 84906316948     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.944507     Document Type: Review

References (144)

1. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294:862-4
2. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853-8
3. Lau NC, Lim LP, Weinstein EG, et al. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001;294:858-62
4. Sempere LF, Cole CN, McPeek MA, et al. The Phylogenetic Distribution of Metazoan microRNAs: Insights into Evolutionary Complexity and Constraint. J Exp Zool B Mol Dev Evol 2006;306:575-88
5. Bartel DP, Chen CZ. Micromanagers of gene expression: The potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004;5:396-400
6. Selbach M, Schwanhausser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs. Nature 2008;455:58-63
7. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009;136: 215-33
8. Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output. Nature 2008;455:64-71
9. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012;148:1172-87
10. Sempere LF, Kauppinen S. Translational implications of MicroRNAs in clinical diagnostics and therapeutics. In: . and Bradshaw RADennis EA, editors. Handbook of cell signaling. 2nd volume. Academic Press; Oxford, UK: 2009. p. 2965-81
11. Ventura A, Jacks T. MicroRNAs and cancer: Short RNAs go a long way. Cell 2009;136:586-91
12. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-89
13. Fabbri M, Calore F, Paone A, et al. Epigenetic regulation of miRNAs in cancer. Adv Exp Med Biol 2013;754:137-48
14. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013;93:98-104
15. Zhang X, Lu X, Lopez-Berestein G, et al. In situ hybridization-based detection of microRNAs in human diseases. microRNA. Diagn Ther 2013;1:12-23
16. Sempere LF. Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn 2011;11: 813-27
17. Spector Y, Fridman E, Rosenwald S, et al. Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas. Mol Oncol 2013;7:732-8
18. Gilad S, Lithwick-Yanai G, Barshack I, et al. Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J Mol Diagn 2012;14: 510-17
19. Meiri E, Mueller WC, Rosenwald S, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 2012;17:801-12
20. Varadhachary GR, Spector Y, Abbruzzese JL, et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 2011;17:4063-70
21. Benjamin H, Lebanony D, Rosenwald S, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn 2010;12:771-9
22. Rosenwald S, Gilad S, Benjamin S, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 2010;23:814-23
23. Szafranska-Schwarzbach AE, Adai AT, Lee LS, et al. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma. Expert Rev Mol Diagn 2011;11:249-57
24. Asuragen. Available from: Http://asuragen. com/products-And-services/ clinical-lab/mirinform-pancreas/
25. Rosetta genomics. Available from: Www. rosettagenomics.com/micrornas- indiagnostics
26. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847-65
27. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368: 1685-94
28. Heppner GH. Tumor heterogeneity. Cancer Res 1984;44:2259-65
29. Martinez P, Birkbak NJ, Gerlinger M, et al. Parallel evolution of tumour subclones mimics diversity between tumours. J Pathol 2013;230:356-64
30. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366: 883-92
31. Klein CA. Selection and adaptation during metastatic cancer progression. Nature 2013;501:365-72
32. Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. Nature 2013;501:355-64
33. Junttila MR, De Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501: 346-54
34. Burrell RA, McGranahan N, Bartek J, et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-45
35. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013;501:328-37
36. Marte B. Tumour heterogeneity. Nature 2013;501:327
37. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013;8:277-302
38. Sempere LF, Preis M, Yezefski T, et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res 2010;16:4246-55
39. Nelson PT, Wilfred BR. In situ hybridization is a necessary experimental complement to microRNA (miRNA) expression profiling in the human brain. Neurosci Lett 2009;466:69-72
40. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9
41. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-9
42. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8
43. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-61
44. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98
45. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801
46. Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005;334: 1351-8
47. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65: 7065-70
48. Liu CG, Calin GA, Meloon B, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA 2004;101: 9740-4
49. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101(32):11755-60
50. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC. Genomics 2006;7:96
51. Nelson PT, Baldwin DA, Kloosterman WP, et al. RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA 2006;12: 187-91
52. De Planell-Saguer M, Rodicio MC. Detection methods for microRNAs in clinic practice. Clin Biochem 2013;46:869-78
53. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: Approaches and considerations. Nat Rev Genet 2012;13: 358-69
54. Kolbert CP, Feddersen RM, Rakhshan F, et al. Multi-platform analysis of microRNA expression measurements in RNA from fresh frozen and FFPE tissues. PLoS One 2013;8:e52517
55. Git A, Dvinge H, Salmon-Divon M, et al. Systematic comparison of microarray profiling, real-Time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010;16: 991-1006
56. Chen C, Ridzon DA, Broomer AJ, et al. Real-Time quantification of microRNAs by stem-loop RT-PCR. Nucleic acids Res 2005;33:e179
57. du Rieu MC, Torrisani J, Selves J, et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010;56:603-12
58. Hannafon BN, Sebastiani P, De las MA, et al. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res 2011;13: R24
59. Grutzmann R, Foerder M, Alldinger I, et al. Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch 2003;443:508-17
60. Zhu L, Yan W, Rodriguez-Canales J, et al. MicroRNA analysis of microdissected normal squamous esophageal epithelium and tumor cells. Am J Cancer Res 2011;1: 574-84
61. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901-8
62. Munding JB, Adai AT, Maghnouj A, et al. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer 2012;131: E86-95
63. Kloosterman WP, Wienholds E, De BE, et al. In situ detection of miRNAs in animal embryos using LNA-modified oligonucleotide probes. Nat Methods 2006;3:27-9
64. Wienholds E, Kloosterman WP, Miska E, et al. MicroRNA Expression in Zebrafish Embryonic Development. Science 2005;309: 310-11
65. Valoczi A, Hornyik C, Varga N, et al. Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes. Nucleic Acids Res 2004;32:e175
66. Kauppinen S, Vester B, Wengel J. Locked nucleic acid: High-Affinity targeting of complementary RNA for RNomics. Handb Exp Pharmacol 2006;405-22
67. Sempere LF, Freemantle S, Pitha-Rowe I, et al. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004;5:R13
68. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002;12:735-9
69. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007;67:11612-20
70. Dillhoff M, Liu J, Frankel W, et al. MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival. J Gastrointest Surg 2008;12: 2171-6
71. Yamamichi N, Shimomura R, Inada K, et al. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res 2009;15:4009-16
72. Habbe N, Koorstra JB, Mendell JT, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009;8:340-6
73. Dyrskjot L, Ostenfeld MS, Bramsen JB, et al. Genomic profiling of microRNAs in bladder cancer: MiR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009;69:4851-60
74. Silahtaroglu AN, Nolting D, Dyrskjot L, et al. Detection of microRNAs in frozen tissue sections by fluorescence in situ hybridization using locked nucleic acid probes and tyramide signal amplification. Nat Protoc 2007;2:2520-8
75. Sempere LF, Korc M. A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. Methods Mol Biol 2013;980:43-59
76. Sempere LF. Fully automated fluorescence-based 4-color multiplex assay for co-detection of microRNA and protein biomarkers in clinical tissue specimens. Methods Mol Med 2014;In press
77. Nielsen BS. MicroRNA in situ hybridization. Methods Mol Biol 2012;822: 67-84
78. Jorgensen S, Baker A, Moller S, et al. Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods 2010;52:375-81
79. Pena JT, Sohn-Lee C, Rouhanifard SH, et al. miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat Methods 2009;6:139-41
80. Singh U, Keirstead N, Wolujczyk A, et al. General principles and methods for routine automated microRNA in situ hybridization and double labeling with immunohistochemistry. Biotech Histochem 2013;89:259-66
81. Renwick N, Cekan P, Masry PA, et al. Multicolor microRNA FISH effectively differentiates tumor types. J Clin Invest 2013;123:2694-702
82. Donnem T, Eklo K, Berg T, et al. Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med 2011;9:6
83. Donnem T, Lonvik K, Eklo K, et al. Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: Coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 2011;117:3193-200
84. Stenvold H, Donnem T, Andersen S, et al. Stage and tissue-specific prognostic impact of miR-182 in NSCLC. BMC Cancer 2014;14:138
85. Stenvold H, Donnem T, Andersen S, et al. High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome. BMC Clin Pathol 2014;14:9
86. Eilertsen M, Andersen S, Al-Saad S, et al. Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer 2014;83:272-8
87. Li J, Yang H, Li Y, et al. microRNA-146 up-regulation predicts the prognosis of non-small cell lung cancer by miRNA in situ hybridization. Exp Mol Pathol 2014;96:195-9
88. Li J, Li X, Li Y, et al. Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS One 2013;8:e53582
89. Jang K, Ahn H, Sim J, et al. Loss of microRNA-200a expression correlates with tumor progression in breast cancer. Transl Res 2014;163:242-51
90. Kadera BE, Li L, Toste PA, et al. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-Associated fibroblasts promotes metastasis. PLoS One 2013;8: E71978
91. Rask L, Balslev E, Jorgensen S, et al. High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. APMIS 2011;119:663-73
92. Hagman Z, Haflidadottir BS, Ceder JA, et al. miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 2013;108:1668-76
93. Schneider M, Andersen DC, Silahtaroglu A, et al. Cell-specific detection of microRNA expression during cardiomyogenesis by combined in situ hybridization and immunohistochemistry. J Mol Histol 2011;42:289-99
94. Nielsen BS, Holmstrom K. Combined microRNA in situ hybridization and immunohistochemical detection of protein markers. Methods Mol Biol 2013;986: 353-65
95. Preis M, Gardner TB, Gordon SR, et al. microRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res 2011;17: 5812-21
96. Liu X, Sempere LF, Guo Y, et al. Involvement of microRNAs in lung cancer biology and therapy. Transl Res 2011;157: 200-8
97. Nielsen BS, Jorgensen S, Fog JU, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011;28:27-38
98. Kjaer-Frifeldt S, Hansen TF, Nielsen BS, et al. The prognostic importance of miR-21 in stage II colon cancer: A population-based study. Br J Cancer 2012;107:1169-74
99. De Planell-Saguer M, Rodicio MC, Mourelatos Z. Rapid in situ codetection of noncoding RNAs and proteins in cells and formalin-fixed paraffin-embedded tissue sections without protease treatment. Nat Protoc 2010;5:1061-73
100. Chaudhuri AD, Yelamanchili SV, Fox HS. Combined fluorescent in situ hybridization for detection of microRNAs and immunofluorescent labeling for cell-Type markers. Front Cell Neurosci 2013;7:160
101. Hanna JA, Wimberly H, Kumar S, et al. Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques 2012;52:235-45
102. Hanna JA, Hahn L, Agarwal S, et al. In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA. Lab Invest 2012;92:1390-7
103. Quesne JL, Jones J, Warren J, et al. Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J Pathol 2012;227:306-14
104. Hansen TF, Sorensen FB, Lindebjerg J, et al. The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer 2012;12:83
105. Hermansen SK, Dahlrot RH, Nielsen BS, et al. MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol 2013;111: 71-81
106. Ma Y, Zhang P, Wang F, et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut 2012;61:1447-53
107. Qian P, Zuo Z, Wu Z, et al. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res 2011;71:6463-74
108. Tang W, Zhu J, Su S, et al. MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One 2012;7:e51702
109. Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272-84
110. Meister J, Schmidt MH. miR-126 and miR-126. *: New players in cancer. ScientificWorldJournal 2010;10:2090-100
111. Metzinger-Le Meuth V, Andrianome S, Chillon JM, et al. microRNAs are dysregulated in the cerebral microvasculature of CKD mice. Front Biosci 2014;6:80-8
112. Nikolic I, Plate KH, Schmidt MH. EGFL7 meets miRNA-126: An angiogenesis alliance. J Angiogenes Res 2010;2:9
113. Schober A, Nazari-Jahantigh M, Wei Y, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 2014;20:368-76
114. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008;79:581-8
115. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15:261-71
116. Anastasov N, Hofig I, Vasconcellos IG, et al. Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells. Radiat Oncol 2012;7:206
117. Bullock MD, Pickard KM, Nielsen BS, et al. Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis 2013;4:e684
118. Wang M, Yang W, Li M, et al. Low expression of miR-150 in pediatric intestinal Burkitt lymphoma. Exp Mol Pathol 2014;96:261-6
119. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-52
120. Schwarzenbach H, Nishida N, Calin GA, et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014;11:145-56
121. Del VV, Cantaloni C, Cucino A, et al. miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol 2011;35: 268-75
122. Fassina A, Cappellesso R, Fassan M. Classification of non-small cell lung carcinoma in trans-Thoracic needle specimens using microRNA expression Profiling. Chest 2011;140:1305-11
123. Bishop JA, Benjamin H, Cholakh H, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010;16:610-19
124. Xing L, Todd NW, Yu L, et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 2010;23:1157-64
125. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009;27: 2030-7
126. Noh S, Shim H. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas. Lung Cancer 2012;76:51-5
127. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25
128. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-Time RT-PCR. Clin Chem 2008;54:1696-704
129. Romero Lauro G, Cable W, Lesniak A, et al. Digital pathology consultations-A new era in digital imaging, challenges and practical applications. J Digit Imaging 2013;26:668-77
130. Ghaznavi F, Evans A, Madabhushi A, et al. Digital imaging in pathology: Whole-slide imaging and beyond. Annu Rev Pathol 2013;8:331-59
131. Sabatier R, Goncalves A, Bertucci F. Personalized medicine: Present and future of breast cancer management. Crit Rev Oncol Hematol 2014. [Epub ahead of print]
132. Jennings L, Van Deerlin VM, Gulley ML, et al. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med 2009;133: 743-55
133. O'Hurley G, Sjostedt E, Rahman A, et al. Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol Oncol 2014;8(4):783-98
134. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010;16:1745-55
135. Cancer therapy evaluation program. Available from: Http://ctep.cancer. gov/
136. Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011;19:116-1122
137. Trang P, Medina PP, Wiggins JF, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010;29:1580-7
138. Cubillos-Ruiz JR, Baird JR, Tesone AJ, et al. Reprogramming tumor-Associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res 2012;72:1683-93
139. Wei J, Feng L, Li Z, et al. MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed Pharmacother 2013;67:387-92
140. Han M, Wang Y, Liu M, et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1alpha expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci 2012;103:1058-64
141. Gene silencing news. Available from: Www. genomeweb.com/rnai/regulus- considers-mir-21-drug-next-clinical-candidate-Amidpositive-Alport-data
142. Liu X, Sempere LF, Galimberti F, et al. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res 2009;15: 1177-83
143. Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120: 1298-309
144. Li T, Li RS, Li YH, et al. miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 2012;187:1466-72